Targeting the Purinome

Methods in Molecular Biology

Volumn 575, Issue , 2009, Pages 47-92

  Murray, Jeremy M ^a   Bussiere, Dirksen E ^a  

^a NONE

Author keywords

ATP binding proteins; Drug design; Drug discovery; Purinome

Indexed keywords

ADENOSINE TRIPHOSPHATE; LIGAND; PHOSPHODIESTERASE; PROTEIN KINASE; PURINE DERIVATIVE; RAS PROTEIN;

AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER PROGRAM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECT; ENZYME ACTIVE SITE; GENETICS; HUMAN; KINETICS; METABOLISM; METHODOLOGY; MOLECULAR BIOLOGY; MOLECULAR GENETICS; PROTEIN BINDING; PROTEIN CONFORMATION; REVIEW; THERMODYNAMICS;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; CATALYTIC DOMAIN; DRUG DESIGN; DRUG DISCOVERY; HUMANS; KINETICS; LIGANDS; MODELS, MOLECULAR; MOLECULAR BIOLOGY; MOLECULAR SEQUENCE DATA; PHOSPHORIC DIESTER HYDROLASES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN KINASES; PURINES; RAS PROTEINS; SOFTWARE DESIGN; THERMODYNAMICS;

MLCS; MLOWN;

EID: 75549084198     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60761-274-2_3     Document Type: Chapter

References (191)

1. Fiske, C.H., and Subbarow, Y. (1929) Phosphorus compounds of muscle and liver. Science 70, 381–2.
2. Lohmann, K. (1929) Über die Pyrophos-phatfraktion im Muskel. Naturwissenschaf-ten 17, 624–5.
3. Meyerhof, O., and Lohmann, K. (1932) Über energetische Wechselbeziehungen zwischen dem Umsatz der Phosphorsäureester im Muskelextrakt. Biochem. Z. 253, 431–61.
4. Lohmann, K. (1935) Konstitution der Adenopyrophosporsäure und Adenosind-phosphosäure. Biochem. Z. 282, 120–3.
5. Makino, K. (1935) Über die Konstitution der Adenosintriphosposäure. Biochem. Z. 278, 161–3.
6. Rall, T.W., and Sutherland, E.W. (1958) Formation of a cyclic adenine ribonucleotide by tissue particles. J. Biol. Chem. 232, 1065–76.
7. Sutherland, E.W., and Rall, T.W. (1958) Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J. Biol. Chem. 232, 1077–91.
8. Haynes, R.C. Jr., Sutherland, E.W., and Rall, T.W. (1960) The role of cyclic adenylic acid in hormone action. Recent. Prog. Horm. Res. 16, 121–38.
9. Birnbaumer, L., Pohl, S.L., Michiel, H., Krans, M.J., and Rodbell, M. (1979) The actions of hormones on the adenyl cyclase system. Adv. Biochem. Psychopharmacol. 3, 185–208.
10. Birnbaumer, L., Pohl, S.L., and Rodbell, M. (1969) Adenyl cyclase in fat cells. 1. Properties and the effects of adrenocorticotropin and fluoride. J. Biol. Chem. 244, 3468–76.
11. Birnbaumer, L., Pohl, S.L., and Rodbell, M. (1971) The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. II. Comparison between glucagon-and fluoride-stimulated activities. J. Biol. Chem. 246, 1857–60.
12. Birnbaumer, L., and Rodbell, M. (1969) Adenyl cyclase in fat cells. II. Hormone receptors. J. Biol. Chem. 244, 3477–82.
13. Pohl, S.L., Birnbaumer, L., and Rodbell, M. (1969) Glucagon-sensitive adenyl cyclase in plasma membrane of hepatic parenchymal cells. Science 164, 566–7.
14. Pohl, S.L., Birnbaumer, L., and Rodbell, M. (1971) The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. I. Properties. J. Biol. Chem. 246, 1849–56.
15. Pohl, S.L., Krans, H.M., Kozyreff, V., Birn-baumer, L., and Rodbell, M. (1971) The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. VI. Evidence for a role of membrane lipids. J. Biol. Chem. 246, 4447–54.
16. Rodbell, M., Birnbaumer, L., Pohl, S.L., and Krans, H.M. (1979) Properties of the adenyl cyclase systems in liver and adipose cells: The mode of action of hormones. Acta Diabetol. Lat. 7(Suppl 1), 9–63.
17. Rodbell, M., Birnbaumer, L., and Pohl, S.L. (1971) Characteristics of glucagon action on the hepatic ade-nylate cyclase system. Biochem. J. 125, 58P-9P.
18. Rodbell, M., Birnbaumer, L., and Pohl, S.L. (1970) Adenyl cyclase in fat cells. 3. Stimulation by secretin and the effects of trypsin on the receptors for lipolytic hormones. J. Biol. Chem. 245, 718–22.
19. Rodbell, M., Birnbaumer, L., Pohl, S.L., and Sundby, F. (1971) The reaction of glu-cagon with its receptor: Evidence for dis-crete regions of activity and binding in the glucagon molecule. Proc. Natl. Acad. Sci. U.S.A. 68, 909–13.
20. Rodbell, M., Krans, H.M., Pohl, S.L., and Birnbaumer, L. (1971) The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. 3. Binding of glucagon: Method of assay and specificity. J. Biol. Chem. 246, 1861–71.
21. Rodbell, M., Krans, H.M., Pohl, S.L., and Birnbaumer, L. (1971) The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. IV. Effects of guan-ylnucleotides on binding of 125I-glucagon. J. Biol. Chem. 246, 1872–6.
22. Rodbell, M., Birnbaumer, L., Pohl, S.L., and Krans, H.M. (1971) The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. V. An obligatory role of guan-ylnucleotides in glucagon action. J. Biol. Chem. 246, 1877–82.
23. Ashman, D.F., Lipton, R., Melicow, M.M., and Price, T.D. (1963) Isolation of adeno-sine 3¢, 5¢-monophosphate and guanosine 3¢, 5¢-monophosphate from rat urine. Biochem. Biophys. Res. Commun. 11, 330–4.
24. Furchgott, R.F., and Zawadzki, J.V. (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373–6.
25. Ignarro, L.J., Buga, G.M., Wood, K.S., Byrns, R.E., and Chaudhuri, G. (1987) Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 84, 9265–9.
26. Ignarro, L.J., Byrns, R.E., Buga, G.M., and Wood, K.S. (1987) Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ. Res. 61, 866–79.
27. Levene, P.A. (1909) Über die Hefenuclein-säure. Biochem. Z. 17, 120–31.
28. Levene, P.A. (1919) The structure of yeast nucleic acid. IV. Ammonia hydrolysis. J. Biol. Chem. 40, 415–24.
29. Haystead, T.A. (2006) The purinome, a complex mix of drug and toxicity targets. Curr. Top. Med. Chem. 6, 1117–27.
30. International Human Genome Sequencing Consortium (2004) Finishing the euchromatic sequence of the human genome. Nature 431, 931–45.
31. Cohen, P. (2002) Protein kinases – the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309–15.
32. Ja, W.W., and Roberts, R.W. (2005) G-protein-directed ligand discovery with peptide combinatorial libraries. Trends Biochem. Sci. 30, 318–24.
33. Marshall, G.R., Head, R.D., and Ragno, R. (2000) Affinity prediction: The sine qua non. In: Di Cera, E. (ed.) Thermodynamics in Biology. Oxford University Press, Oxford, pp. 87–111.
34. Holdgate, G.A., and Ward, W.H. (2005) Measurements of binding thermodynamics in drug discovery. Drug Discov. Today 10, 1543–50.
35. Knapp, M., Bellamacina, C., Murray, J.M., and Bussiere, D.E. (2006) Targeting cancer: The challenges and successes of structure-based drug design against the human purinome. Curr. Top. Med. Chem. 6, 1129–59.
36. Traut, T.W. (1994) Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 140, 1–22.
37. Cheng, Y., and Prusoff, W.H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–108.
38. Ghaemmaghami, S., Huh, W.K., Bower, K., et al. (2003) Global analysis of protein expression in yeast. Nature 425, 737–41.
39. Knight, Z.A., and Shokat, K.M. (2005) Features of selective kinase inhibitors. Chem. Biol. 12, 621–37.
40. Arooz, T., Yam, C.H., Siu, W.Y., Lau, A., Li, K.K., and Poon, R.Y. (2000) On the concentrations of cyclins and cyclin-dependent kinases in extracts of cultured human cells. Biochemistry 39, 9494–501.
41. Bhatt, R.R., and Ferrell, J.E. Jr. (2000) Cloning and characterization of Xenopus Rsk2, the predominant p90 Rsk isozyme in oocytes and eggs. J. Biol. Chem. 275, 32983–90.
42. Hopkins, A.L., and Groom, C.R. (2002) The druggable genome. Nat. Rev. Drug Discov. 1, 727–30.
43. Keller, T.H., Pichota, A., and Yin, Z. (2006) A practical view of ‘druggability’. Curr. Opin. Chem. Biol. 10, 357–61.
44. Walke, D.W., Han, C., Shaw, J., Wann, E., Zambrowicz, B., and Sands, A. (2001) In vivo drug target discovery: Identifying the best targets from the genome. Curr. Opin. Biotechnol. 12, 626–31.
45. Schneider, M. (2004) A rational approach to maximize success rate in target discovery. Arch. Pharm. 337, 625–33.
46. Peters, K.P., Fauck, J., and Frommel, C. (1996) The automatic search for ligand binding sites in proteins of known three-dimensional structure using only geometric criteria. J. Mol. Biol. 256, 201–13.
47. Liang, J., Edelsbrunner, H., and Woodward, C. (1998) Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand design. Protein Sci. 7, 1884–97.
48. Hendlich, M., Rippmann, F., and Barnickel, G. (1997) LIGSITE: Automatic and efficient detection of potential small molecule-binding sites in proteins. J. Mol. Graph. Model. 15, 359–63.
49. Brady, G.P. Jr., and Stouten, P.F. (2000) Fast prediction and visualization of protein binding pockets with PASS. J. Comput. Aided Mol. Des. 14, 383–401.
50. An, J., Totrov, M., and Abagyan, R. (2005) Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol. Cell Proteomics 4, 752–61.
51. Laskowski, R.A. (1995) SURFNET: A program for visualizing molecular surfaces, cavities, and intermolecular interactions. J. Mol. Graph. 13, 323–30.
52. Goodford, P.J. (1985) A computational procedure for determining energetically favorable binding sites on biologically important macro-molecules. J. Med. Chem. 28, 849–57.
53. Kortvelyesi, T., Dennis, S., Silberstein, M., Brown, L. III, and Vajda, S. (2003) Algorithms for computational solvent mapping of proteins. Proteins 51, 340–51.
54. Silberstein, M., Dennis, S., Brown, L., Kortvelyesi, T., Clodfelter, K., and Vajda, S. (2003) Identification of substrate binding sites in enzymes by computational solvent mapping. J. Mol. Biol. 332, 1095–113.
55. Hajduk, P.J., Huth, J.R., and Fesik, S.W. (2005) Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 48, 2518–25.
56. Brunger, A.T. (1997) X-ray crystallography and NMR reveal complementary views of structure and dynamics. Nat. Struct. Biol. 4 (Suppl), 862–5.
57. Krebs, E.G., and Beavo, J.A. (1979) Phos-phorylation-dephosphorylation of enzymes. Annu. Rev. Biochem. 48, 923–59.
58. Nestler, E.J., and Greengard, P (1983). Protein phosphorylation in the brain. Nature 305, 583–8.
59. Lohmann, S.M., Walter, U., and Greengard, P. (1980) Identification of endogenous substrate proteins for cAMP-dependent protein kinase in bovine brain. J. Biol. Chem. 255, 9985–92.
60. Langan, T.A. (1968) Histone phosphorylation: Stimulation by adenosine 3¢,5¢-mono-phosphate. Science 162, 579–80.
61. Mayer, S.E., and Krebs, E.G. (1970) Studies on the phosphorylation and activation of skeletal muscle phosphorylase and phos-phorylase kinase in vivo. J. Biol. Chem. 245, 3153–60.
62. Krebs, E.G., and Stull, J.T. (1975) Protein phosphorylation and metabolic control. Ciba Found. Symp. 31, 355–67.
63. Cobbs, W.H., Barkdoll, A.E. III, and Pugh, E.N. Jr. (1985) Cyclic GMP increases photocurrent and light sensitivity of retinal cones. Nature 317, 64–6.
64. Kurkin, S.A., Kislov, A.N., and Fesenko, E.E. (1982) Conductance of cytoplasmic membrane of photoreceptors by the method of intracellular dialysis. Biofizika 27, 1053–6.
65. Yau, K.W., and Nakatani, K. (1985) Light-suppressible, cyclic GMP-sensitive conductance in the plasma membrane of a truncated rod outer segment. Nature 317, 252–5.
66. Bruch, R.C., and Kalinoski, D.L. (1987) Interaction of GTP-binding regulatory proteins with chemosensory receptors. J. Biol. Chem. 262, 2401–4.
67. Striem, B.J., Pace, U., Zehavi, U., Naim, M., and Lancet, D. (1989) Sweet tastants stimulate adenylate cyclase coupled to GTP-binding protein in rat tongue membranes. Biochem. J. 260, 121–6.
68. Butcher, R.W., and Sutherland, E.W. (1962) Adenosine 3¢,5¢-phosphate in biological materials. I. Purification and properties of cyclic 3¢,5¢-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3¢,5¢-phosphate in human urine. J. Biol. Chem. 237, 1244–50.
69. Beavo, J.A., Conti, M., and Heaslip, R.J. (1994) Multiple cyclic nucleotide phosphodi-esterases. Mol. Pharmacol. 46, 399–405.
70. Wang, H., Liu, Y., Hou, J., Zheng, M., Robinson, H., and Ke, H. (2007) Structural insight into substrate specificity of phosphodiesterase 10. Proc. Natl. Acad. Sci. U.S.A. 104, 5782–7.
71. Wang, H., Liu, Y., Chen, Y., Robinson, H., and Ke, H. (2005) Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7. J. Biol. Chem. 280, 30949–55.
72. Iffland, A., Kohls, D., Low, S., et al. (2005) Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system. Biochemistry 44, 8312–25.
73. Huai, Q., Colicelli, J., and Ke, H. (2003) The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry 42, 13220–6.
74. Huai, Q., Wang, H., Sun, Y., Kim, H.Y., Liu, Y., and Ke, H. (2003) Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure 11, 865–73.
75. Xu, R.X., Hassell, A.M., Vanderwall, D., et al. (2000) Atomic structure of PDE4: Insights into phosphodiesterase mechanism and specificity. Science 288, 1822–5.
76. Lee, M.E., Markowitz, J., Lee, J.O., and Lee, H. (2002) Crystal structure of phosphodiesterase 4D and inhibitor complex(1). FEBS Lett. 530, 53–8.
77. Sung, B.J., Hwang, K.Y., Jeon, Y.H., et al. (2003) Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 425, 98–102.
78. Huai, Q., Wang, H., Zhang, W., Colman, R.W., Robinson, H., and Ke, H. (2004) Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc. Natl. Acad. Sci. U.S.A. 101, 9624–9.
79. Xu, R.X., Rocque, W.J., Lambert, M.H., Vanderwall, D.E., Luther, M.A., and Nolte, R.T. (2004) Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram. J. Mol. Biol. 337, 355–65.
80. Scapin, G., Patel, S.B., Chung, C., et al. (2004) Crystal structure of human phosphodiesterase 3B: Atomic basis for substrate and inhibitor specificity. Biochemistry 43, 6091–100.
81. Liu, S., Mansour, M.N., Dillman, K.S., et al. (2008) Structural basis for the catalytic mechanism of human phosphodiesterase 9. Proc. Natl. Acad. Sci. U.S.A. 105, 13309–14.
82. Card, G.L., England, B.P., Suzuki, Y., et al. (2004) Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 12, 2233–47.
83. Beavo, J.A. (1995) Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol. Rev. 75, 725–48.
84. Zhang, K.Y., Card, G.L., Suzuki, Y., et al. (2004) A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol. Cell. 15, 279–86.
85. Francis, S.H., Colbran, J.L., McAllister-Lucas, L.M., and Corbin, J.D. (1994) Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase. J. Biol. Chem. 269, 22477–80.
86. Rotella, D.P. (2002) Phosphodiesterase 5 inhibitors: Current status and potential applications. Nat. Rev. Drug Discov. 1, 674–82.
87. Haning, H., Niewohner, U., Schenke, T., Lampe, T., Hillisch, A., and Bischoff, E. (2005) Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors. Bioorg. Med. Chem. Lett. 15, 3900–7.
88. Rotella, D.P. (2006) Phosphodiesterases. In: Taylor, J.D., and Triggle, D.J. (eds.) Comprehensive Medicinal Chemistry II. Elsevier, Oxford, pp. 919–57.
89. Haning, H., Niewoehner, U., Bischoff, E. (2003) Phosphodiesterase Type 5 (PDE5) Inhibitors. Progress in Medicinal Chemistry 41, 246–306.
90. Sekhar, K.R., Grondin, P., Francis, S.H., and Corbin, J.D. (1996) Design and synthesis of xanthines and cyclic GMP analogues as potent inhibitors of PDE5. In: Schudt, C. (ed.) The Handbook of Immunopharmacology. Academic Press, New York, pp. 135–46.
91. Huai, Q., Liu, Y., Francis, S.H., Corbin, J.D., and Ke, H. (2004) Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity. J. Biol. Chem. 279, 13095–101.
92. Kramer, G.L., and Wells, J.N. (1979) Effects of phosphodiesterase inhibitors on cyclic nucleotide levels and relaxation of pig coronary arteries. Mol. Pharmacol. 16, 813–22.
93. Garst, J.E., Kramer, G.L., Wu, Y.J., and Wells, J.N. (1976) Inhibition of separated forms of phosphodiesterases from pig coronary arteries by uracils and by 7-substituted derivatives of 1-methyl-3-isobutylxanthine. J. Med. Chem. 19, 499–503.
94. Wang, H., Liu, Y., Huai, Q., et al. (2006) Multiple conformations of phosphodieste-rase-5: Implications for enzyme function and drug development. J. Biol. Chem. 281, 21469–79.
95. Eros, D., Szantai-Kis, C., Kiss, R., et al. (2008) Structure-activity relationships of PDE5 inhibitors. Curr. Med. Chem. 15, 1570–85.
96. Manning, G., Whyte, D.B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912–34.
97. Adams, JA. (2001) Kinetic and catalytic mechanisms of protein kinases. Chem Rev 101, 2271–90.
98. Ubersax, J.A., and Ferrell, J.E. Jr. (2007) Mechanisms of specificity in protein phosphorylation. Nat. Rev. Mol. Cell. Biol. 8, 530–41.
99. Benson, J.D., Chen, Y.N., Cornell-Kennon, S.A., et al. (2006) Validating cancer drug targets. Nature 441, 451–6.
100. Walker, I., and Newell, H. (2009) Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Discov. 8, 15–6.
101. Vieth, M., Higgs, R.E., Robertson, D.H., Shapiro, M., Gragg, E.A., and Hemmerle, H. (2004) Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 1697, 243–57.
102. Karaman, M.W., Herrgard, S., Treiber, D.K., et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127–32.
103. Liu, Y., Shah, K., Yang, F., Witucki, L., and Shokat, K.M. (1998) A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Bioorg. Med. Chem. 6, 1219–26.
104. Liu, Y., Shah, K., Yang, F., Witucki, L., and Shokat, K.M. (1998) Engineering Src family protein kinases with unnatural nucleotide specificity. Chem. Biol. 5, 91–101.
105. Bishop, A.C., and Shokat, K.M. (1999) Acquisition of inhibitor-sensitive protein kinases through protein design. Pharmacol. Ther. 82, 337–46.
106. Blencke, S., Zech, B., Engkvist, O., et al. (2004) Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem. Biol. 11, 691–701.
107. Alaimo, P.J., Knight, Z.A., and Shokat, K.M. (2005) Targeting the gatekeeper residue in phosphoinositide 3-kinases. Bioorg. Med. Chem. 13, 2825–36.
108. Liu, Y., and Gray, N.S. (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358–64.
109. Manley, P.W., Cowan-Jacob, S.W., and Mestan, J. (2005) Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim. Bio-phys. Acta. 1754, 3–13.
110. Lee, J.C., Kassis, S., Kumar, S., Badger, A., and Adams, J.L. (1999) p38 mitogen-activated protein kinase inhibitors – mechanisms and therapeutic potentials. Pharmacol. Ther. 82, 389–97.
111. Wilson, K.P., McCaffrey, P.G., Hsiao, K., et al. (1997) The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 4, 423–31.
112. Wang, Z., Canagarajah, B.J., Boehm, J.C., et al. (1998) Structural basis of inhibitor selectivity in MAP kinases. Structure 6, 1117–28.
113. Zhang, Q., Liu, Y., Gao, F., et al. (2006) Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library. J. Am. Chem. Soc. 128, 2182–3.
114. Ghose, A.K., Herbertz, T., Pippin, D.A., Salvino, J.M., and Mallamo, J.P. (2008) Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. J.Med. Chem. 51, 5149–71.
115. Bohmer, F.D., Karagyozov, L., Uecker, A., et al. (2003) A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J. Biol. Chem. 278, 5148–55.
116. Honma, T., Yoshizumi, T., Hashimoto, N., et al. (2001) A novel approach for the development of selective Cdk4 inhibitors: Library design based on locations of Cdk4 specific amino acid residues. J. Med. Chem. 44, 4628–40.
117. Teague, S.J. (2003) Implications of protein flexibility for drug discovery. Nat. Rev. Drug Discov. 2, 527–41.
118. Huse, M., and Kuriyan, J. (2002) The conformational plasticity of protein kinases. Cell 109, 275–82.
119. Wood, E.R., Truesdale, A.T., McDonald, O.B., et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652–9.
120. Heron, N.M., Anderson, M., Blowers, D.P., et al. (2005) SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg. Med. Chem. Lett. 16, 1320–3.
121. Bellon, S.F., Kaplan-Lefko, P., Yang, Y., et al (2008) c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J. Biol. Chem. 283, 2675–83.
122. Stamos, J., Sliwkowski, M.X., and Eigenbrot, C. (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277, 46265–72.
123. Kufareva, I., and Abagyan, R. (2008) Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J. Med. Chem. 51, 7921–32.
124. Vale, R.D., and Milligan, R.A. (2000) The way things move: Looking under the hood of molecular motor proteins. Science 288, 88–95.
125. Sakowicz, R., Finer, J.T., Beraud, C., et al. (2004) Antitumor activity of a kinesin inhibitor. Cancer Res. 64, 3276–80.
126. Kolomeisky, A.B., and Fisher, M.E. (2007) Molecular motors: A theorist’s perspective. Annu. Rev. Phys. Chem. 58, 675–95.
127. Vale, R.D., and Fletterick, R.J. (1997) The design plan of kinesin motors. Annu. Rev. Cell Dev. Biol. 13, 745–77.
128. Vetter, I.R., and Wittinghofer, A. (1999) Nucleoside triphosphate-binding proteins: Different scaffolds to achieve phosphoryl transfer. Q. Rev. Biophys. 32, 1–56.
129. Turner, J., Anderson, R., Guo, J., Beraud, C., Fletterick, R., and Sakowicz, R. (2001) Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the neck-linker. J. Biol. Chem. 276, 25496–502.
130. Sablin, E.P., Kull, F.J., Cooke, R., Vale, R.D., and Fletterick, R.J. (1996) Crystal structure of the motor domain of the kinesin-related motor ncd. Nature 380, 555–9.
131. Kull, F.J., Sablin, E.P., Lau, R., Fletterick, R.J., and Vale, R.D. (1996) Crystal structure of the kinesin motor domain reveals a structural similarity to myosin. Nature 380, 550–5.
132. Lad, L., Luo, L., Carson, J.D., et al. (2008) Mechanism of inhibition of human KSP by ispinesib. Biochemistry 47, 3576–85.
133. Hopkins, S.C., Vale, R.D., and Kuntz, I.D. (2000) Inhibitors of kinesin activity from structure-based computer screening. Biochemistry 39, 2805–14.
134. Mayer, T.U., Kapoor, T.M., Haggarty, S.J., King, R.W., Schreiber, S.L., and Mitchison, T.J. (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286, 971–4.
135. Maliga, Z., Kapoor, T.M., and Mitchison, T.J. (2002) Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. Chem. Biol. 9, 989–96.
136. Luo, L., Carson, J.D., Dhanak, D., et al. (2004) Mechanism of inhibition of human KSP by monastrol: Insights from kinetic analysis and the effect of ionic strength on KSP inhibition. Biochemistry 43, 15258–66.
137. Yan, Y.W., Sardana, V., Xu, B., et al. (2004) Inhibition of a mitotic motor protein: Where, how, and conformational consequences. J. Mol. Biol. 335, 547–54.
138. Zhang, B., Liu, J.F., Xu, Y., and Ng, S.C. (2008) Crystal structure of HsEg5 in complex with clinical candidate CK0238273 provides insight into inhibitory mechanism, potency, and specificity. Biochem. Biophys. Res. Commun. 372, 565–70.
139. Zhang, Y., and Xu, W. (2008) Progress on kinesin spindle protein inhibitors as anti-cancer agents. Anticancer Agents Med. Chem. 8, 698–704.
140. Liu, F., You, Q.D., and Chen, Y.D. (2006) Pharmacophore identification of KSP inhibitors. Bioorg. Med. Chem. Lett. 17, 722–6.
141. Maliga, Z., and Mitchison, T.J. (2006) Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol. BMC Chem. Biol. 6, 2.
142. Brier, S., Lemaire, D., DeBonis, S., Forest, E., and Kozielski, F. (2006) Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents. J. Mol. Biol. 360, 360–76.
143. Rickert, K.W., Schaber, M., Torrent, M., et al. (2008) Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP. Arch. Biochem. Biophys. 469, 220–31.
144. Parrish, C.A., Adams, N.D., Auger, K.R., et al. (2007) Novel ATP-competitive kinesin spindle protein inhibitors. J. Med. Chem. 50, 4939–52.
145. Tecle, H., Shao, J., Li, Y., et al. (2009) Beyond the MEK-pocket: Can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK? Bioorg. Med. Chem. Lett. 19, 226–9.
146. Lewis, J.A., Lebois, E.P., and Lindsley, C.W. (2008) Allosteric modulation of kinases and GPCRs: Design principles and structural diversity. Curr. Opin. Chem. Biol. 12, 269–80.
147. Downward, J. (1998) Ras signalling and apoptosis. Curr. Opin. Genet. Dev. 8, 49–54.
148. Buday, L., and Downward, J. (2008) Many faces of Ras activation. Biochim. Biophys. Acta. 1786, 178–87.
149. Nakao, M., Janssen, J.W., Seriu, T., and Bartram, C.R. (2000) Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology. Leukemia 14, 312–5.
150. Burmer, G.C., and Loeb, L.A. (1989) Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc. Natl. Acad. Sci. U.S.A. 86, 2403–7.
151. Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., and Perucho, M. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549–54.
152. Bourne, H.R., Sanders, D.A., and McCor-mick, F. (1991) The GTPase superfamily: Conserved structure and molecular mechanism. Nature 349, 117–27.
153. Paduch, M., Jelen, F., and Otlewski, J. (2001) Structure of small G proteins and their regulators. Acta Biochim. Pol. 48, 829–50.
154. Feuerstein, J., Kalbitzer, H.R., John, J., Goody, R.S., and Wittinghofer, A. (1987) Characterisation of the metal-ion-GDP complex at the active sites of transforming and nontransforming p21 proteins by observation of the 17O-Mn superhyperfine coupling and by kinetic methods. Eur. J. Biochem. 162, 49–55.
155. Ahmadian, M.R. (2002) Prospects for anti-ras drugs. Br. J. Haematol. 116, 511–8.
156. Dever, T.E., Glynias, M.J., and Merrick, W.C. (1987) GTP-binding domain: Three consensus sequence elements with distinct spacing. Proc Natl Acad Sci U.S.A. 84, 1814–8.
157. Scheidig, A.J., Franken, S.M., Corrie, J.E., et al. (1995) X-ray crystal structure analysis of the catalytic domain of the oncogene product p21H-ras complexed with caged GTP and mant dGppNHp. J. Mol. Biol. 253, 132–50.
158. Zhong, J.M., Chen-Hwang, M.C., and Hwang, Y.W. (1995) Switching nucleotide specificity of Ha-Ras p21 by a single amino acid substitution at aspartate 119. J. Biol. Chem. 270, 10002–7.
159. Schmidt, G., Lenzen, C., Simon, I., et al. (1996) Biochemical and biological consequences of changing the specificity of p21ras from guanosine to xanthosine nucleotides. Oncogene 12, 87–96.
160. Kosloff, M., and Selinger, Z. (2001) Substrate assisted catalysis – application to G proteins. Trends Biochem. Sci. 26, 161–6.
161. Kosloff, M., and Selinger, Z. (2003) GTPase catalysis by Ras and other G-proteins: Insights from substrate directed superimposition. J. Mol. Biol. 331, 1157–70.
162. Frech, M., Darden, T.A., Pedersen, L.G., et al. (1994) Role of glutamine-61 in the hydrolysis of GTP by p21H-ras: An experimental and theoretical study. Biochemistry 33, 3237–44.
163. Nassar, N., Horn, G., Herrmann, C., Scherer, A., McCormick, F., and Witting-hofer, A. (1995) The 2.2 A crystal structure of the Ras-binding domain of the serine/ threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue. Nature 375, 554–60.
164. Zhang, J., and Matthews, C.R. (1998) Ligand binding is the principal determinant of stability for the p21(H)-ras protein. Biochemistry 37, 14881–90.
165. Zhang, J., and Matthews, C.R. (1998) The role of ligand binding in the kinetic folding mechanism of human p21(H-ras) protein. Biochemistry 37, 14891–9.
166. Spoerner, M., Herrmann, C., Vetter, I.R., Kalbitzer, H.R., and Wittinghofer, A. (2001) Dynamic properties of the Ras switch I region and its importance for binding to effectors. Proc. Natl. Acad. Sci. U.S.A. 98, 4944–9.
167. Geyer, M., Schweins, T., Herrmann, C., Prisner, T., Wittinghofer, A., and Kalbitzer, H.R. (1996) Conformational transitions in p21ras and in its complexes with the effector protein Raf-RBD and the GTPase activating protein GAP. Biochemistry 35, 10308–20.
168. Al-Mulla, F., Milner-White, E.J., Going, J.J., and Birnie, G.D. (1999) Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J. Pathol. 187, 433–8.
169. Herrmann, C., Block, C., Geisen, C., et al. (1998) Sulindac sulfide inhibits Ras signaling. Oncogene 17, 1769–76.
170. Waldmann, H., Karaguni, M.I., Carpintero, M., et al (2004) Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway. Angew. Chem. Int. Ed. Engl. 43, 454–8.
171. Kyte, J. (2003) The basis of the hydrophobic effect. Biophys. Chem. 100, 193–203.
172. Ruelle, P., and Kesselring, U.W. (1998) The hydrophobic effect. 1. A consequence of the mobile order in H-bonded liquids. J. Pharm. Sci. 87, 987–97.
173. Ruelle, P., and Kesselring, U.W. (1998) The hydrophobic effect. 2. Relative importance of the hydrophobic effect on the solubility of hydrophobes and pharmaceuticals in H-bonded solvents. J. Pharm. Sci. 87, 998–1014.
174. Ruelle, P., and Kesselring, U.W. (1998) The hydrophobic effect. 3. A key ingredient in predicting n-octanol-water partition coefficients. J. Pharm. Sci. 87, 1015–24.
175. Sharp, K.A., Nicholls, A., Fine, R.F., and Honig, B. (1991) Reconciling the magnitude of the microscopic and macroscopic hydrophobic effects. Science 252, 106–9.
176. Honig, B., Sharp, K., and Gilson, M. (1989) Electrostatic interactions in proteins. Prog. Clin. Biol. Res. 289, 65–74.
177. Sharp, K.A., and Honig, B. (1990) Electrostatic interactions in macromolecules: Theory and applications. Annu. Rev. Biophys. Biophys. Chem. 19, 301–32.
178. Sinha, N, and Smith-Gill, S.J. (2002) Electrostatics in protein binding and function. Curr. Protein Pept. Sci. 3, 601–14.
179. Paulini, R., Muller, K., and Diederich, F. (2005) Orthogonal multipolar interactions in structural chemistry and biology. Angew. Chem. Int. Ed. Engl. 44, 1788–805.
180. Israelachvili, J.N. (1973) Van der Waals forces in biological systems. Q. Rev. Biophys. 16, 341–87.
181. Fleming, P.J., and Rose, G.D. (2005) Do all backbone polar groups in proteins form hydrogen bonds? Protein Sci. 14, 1911–7.
182. Perrin, C.L., and Nielson, J.B. (1997) “Strong” hydrogen bonds in chemistry and biology. Annu. Rev. Phys. Chem. 48, 511–44.
183. Kim, K.S., Tarakeshwar, P., and Lee, J.Y. (2000) Molecular clusters of pi-systems: Theoretical studies of structures, spectra, and origin of interaction energies. Chem Rev 100, 4145–86.
184. McGaughey, G.B., Gagne, M., and Rappe, A.K. (1998) pi-Stacking interactions. Alive and well in proteins. J. Biol. Chem. 273, 15458–63.
185. Sinnokrot, M.O., and Sherrill, C.D. (2004) Substituent effects in pi-pi interactions: Sandwich and T-shaped configurations. J. Am. Chem. Soc. 126, 7690–7.
186. Crowley, P.B., and Golovin, A. (2005) Cation–pi interactions in protein–protein inter-faces. Proteins 59, 231–9.
187. Cubero, E., Luque, F.J., and Orozco, M. (1998) Is polarization important in cation-pi interactions? Proc. Natl. Acad. Sci. U.S.A. 95, 5976–80.
188. Gallivan, J.P, and Dougherty, D.A. (1999) Cation– pi interactions in structural biology. Proc. Natl. Acad. Sci. U.S.A. 96, 9459–64.
189. Wittinghofer, A., and Waldmann, H. Ras – A molecular switch involved in tumor formation. Angew. Chem. Int. Ed. Engl. 39, 4192–214
190. Noonan, T., Brown, N., Dudycz, L., and Wright, G. (1991) Interaction of GTP derivatives with cellular and oncogenic ras-p21 proteins. J. Med. Chem. 34, 1302–7.
191. Ahmadian, MR. (2002) Prospects for anti-ras drugs. Br. J. Haematol. 116, 511–8.